Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. - Galanello,R.; Piga,A.; Forni,GL.; Bertrand,Y.; Foschini,ML.; Bordone,E.; Leoni,G.; Lavagetto,A.; Zappu,A.; Longo,F.; Maseruka,H.; Hewson,N.; et al. (Haematologica/THJ, 2006)